natgillin/translations-raw huggingface dataset:
Tell your doctor if you or your family/carer notices you are developing urges or cravings to behave in ways that are unusual for you or you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. 
Obavijestite svog liječnika ako Vi ili Vaša obitelj/osoba koja se brine o Vama primijeti da se kod Vas razvijaju porivi ili neobuzdana želja da se ponašate na način koji je neuobičajen za Vas ili da se ne možete oduprijeti porivu, nagonu ili iskušenju da napravite nešto što bi moglo naštetiti Vama ili drugima.
(≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data, since no valid estimate can be derived from clinical trials or epidemiological studies). 
rijetko (≥1/10 000, <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka, budući da se iz kliničkih ili epidemioloških ispitivanja ne može izvući valjana procjena).
EU/1/10/665/001 - 30 tablets EU/1/10/665/002 - 60 tablets EU/1/10/665/003 - 100 tablets EU/1/10/665/004 - 175 tablets 
EU/1/10/665/001 - 30 tableta EU/1/10/665/002 - 60 tableta EU/1/10/665/003 - 100 tableta EU/1/10/665/004 - 175 tableta
Week 8-24 66.8±14.5 
Početna vrijednost Tjedan 8-24 66,8±14,5
EU/1/10/665/002 - 60 tablets EU/1/10/665/003 - 100 tablets EU/1/10/665/004 - 175 tablets 
EU/1/10/665/002 - 60 tableta EU/1/10/665/003 - 100 tableta EU/1/10/665/004 - 175 tableta
Dyskinesias (27%), nausea (11%), diarrhoea (8%), abdominal pain (7%) and dry mouth (4.2%) were reported significantly more often with entacapone than with placebo in pooled data from clinical studies involving 406 patients taking the medicinal product and 296 patients taking placebo. 
Diskinezije (27%), mučnina (11%), proljev (8%), bol u trbuhu (7%) i suhoća usta (4,2%) zabilježene su značajno češće s entakaponom nego s placebom u objedinjenim podacima iz kliničkih ispitivanja koja su uključivala 406 bolesnika koji su uzimali lijek i 296 bolesnika koji su uzimali placebo.
This leads to a higher levodopa AUC. 
To dovodi do povećanja AUC levodope.
It is a reversible, specific, and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa preparations. 
On je reverzibilan, specifičan i uglavnom periferno aktivan inhibitor COMT namijenjen za istovremenu primjenu s preparatima levodope.
Hepatitis with mainly cholestatic features (see section 4.4.) 
Hepatitis s uglavnom kolestatskim obilježjima (vidjeti dio 4.4)
Entacapone is extensively bound to plasma proteins, mainly to albumin. 
Entakapon se u velikoj mjeri veže na proteine plazme, uglavnom na albumin.
How to store Entacapone Teva Contents of the pack and other information 
Kako čuvati Entakapon Teva Sadržaj pakiranja i druge informacije
Due to its affinity to cytochrome P450 2C9 in vitro (see section 5.2), entacapone may potentially interfere with medicinal products with metabolism dependent on this isoenzyme, such as S-warfarin. 
Zbog svog afiniteta prema citokromu P450 2C9 in vitro (vidjeti dio 5.2), entakapon može potencijalno interferirati s lijekovima čiji metabolizam ovisi o ovom izoenzimu, kao što je S-varfarin.
Pharmacotherapeutic group: other dopaminergic agents, ATC code: N04BX02. 
Farmakoterapijska skupina: ostali dopaminergici, ATK oznaka: N04BX02.
Data from in vitro studies using human liver microsomal preparations indicate that entacapone inhibits cytochrome P450 2C9 (IC50 ~4 μM). 
Podaci iz in vitro ispitivanja uz korištenje humanih jetrenih mikrosomalnih preparata pokazuju da entakapon inhibira citokrom P450 2C9 (IC50 ~ 4 μM).
In animal studies entacapone was excreted in milk. 
U ispitivanjima na životinjama, entakapon se izlučivao mlijekom.
Other medicines and Entacapone Teva 
Drugi lijekovi i Entakapon Teva
Weight decrease * Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon 
* Nuspojave su poredane prema učestalosti, pri čemu se na početku navode najčešće, koristeći sljedeće izraze: vrlo često (≥1/10), često (≥1/100, <1/10), manje često (≥1/1000, <1/100),
Entacapone inhibits the COMT enzyme mainly in peripheral tissues. 
Entakapon inhibira enzim COMT uglavnom u perifernim tkivima.
These behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or a preoccupation with an increase in sexual thoughts or feelings. 
Ta se ponašanja nazivaju poremećaji kontrole impulsa i mogu uključivati ovisnost o kockanju, pretjerano jedenje ili trošenje, pretjerano pojačan seksualni nagon ili učestala zaokupljenost seksualnim mislima ili osjećajima.
Do not use this medicine after the expiry date which is stated on the carton and tablet container label after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i na naljepnici spremnika za tablete iza oznake EXP.
No overt teratogenic or primary foetotoxic effects were observed in animal studies in which the exposure levels of entacapone were markedly higher than the therapeutic exposure levels. 
Nisu opaženi očiti teratogeni niti primarni fetotoksični učinci u ispitivanjima na životinjama, u kojima su razine izloženosti entakaponu bile značajno više od terapijskih razina izloženosti.
Only traces of entacapone are found unchanged in urine. 
U mokraći su nađeni samo tragovi nepromijenjenog entakapona.
• if you have ever suffered from a rare reaction to antipsychotic medicines called neuroleptic malignant syndrome (NMS). 
• ako ste ikad imali rijetku reakciju na antipsihotike zvanu neuroleptički maligni sindrom
TEVA UK Ltd Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, United Kingdom 
TEVA UK Ltd Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, Ujedinjeno Kraljevstvo
Mogilska 80, 31-546, Krakow Poland 
Mogilska 80, 31-546, Krakow Poljska
Clinical interaction studies with diazepam and non-steroidal antiinflammatory medicinal products have not been carried out. 
Klinička ispitivanja interakcija s diazepamom i nesteroidnim protuupalnim lijekovima nisu provedena.
However, for patients who are receiving dialysis therapy, a longer dosing interval may be considered (see section 5.2). 
Međutim, u bolesnika na dijalizi može se razmotriti mogućnost produljenja intervala doziranja (vidjeti dio 5.2).
COMT inhibition in red blood cells closely follows the plasma concentrations of entacapone, thus clearly indicating the reversible nature of COMT inhibition. 
Inhibicija COMT u eritrocitima vjerno prati koncentracije entakapona u plazmi, što jasno upućuje na reverzibilnu prirodu inhibicije COMT.
Mogilska 80, 31-546, Krakow, Poland 
Mogilska 80, 31-546, Krakow, Poljska
If you are receiving dialysis for renal insufficiency, your doctor may tell you to increase the time between doses. 
Ako zbog zatajenja bubrega idete na dijalizu, liječnik Vam može reći da povećate vremenski razmak između doza.
Prolonged or persistent diarrhoea appearing during use of entacapone may be a sign of colitis. 
Produljeni ili dugotrajni proljev koji se javlja tijekom primjene entakapona može biti znak kolitisa.
- Phaeochromocytoma. 
- Feokromocitom.
Entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations. 
Entakapon je indiciran kao dodatak standardnim preparatima levodope/benzerazida ili levodope/karbidope, za primjenu u odraslih bolesnika s Parkinsonovom bolešću i motoričkim fluktuacijama pri kraju doze koji se ne mogu stabilizirati tim kombinacijama.
The acute symptoms and signs in these cases of overdose included confusion, decreased activity, somnolence, hypotonia, skin discolouration and urticaria. 
Akutni simptomi i znakovi u ovim su slučajevima predoziranja uključivali konfuziju, smanjenu aktivnost, somnolenciju, hipotoniju, promjene boje kože i urtikariju.
Week 8-24 10.7±2.2 
Početna vrijednost Tjedan 8-24 10,7±2,2
if you experience increasing loss of appetite, weakness, exhaustion and weight loss within a relatively short period of time, a general medical evaluation including liver function should be considered. 
• ako imate povećani gubitak apetita, slabost, iscrpljenost i gubitak tjelesne težine unutar relativno kratkog vremenskog perioda, potrebno je razmisliti o općem liječničkom pregledu, uključujući pretragu jetrene funkcije.
In human plasma the unbound fraction is about 2.0% in the therapeutic concentration range. 
Udio nevezanog lijeka u ljudskoj plazmi iznosi oko 2% u rasponu terapijskih koncentracija.
- Concomitant use of a selective MAO-A inhibitor plus a selective MAO-B inhibitor and entacapone (see section 4.5). 
- Istovremena primjena selektivnog MAO-A inhibitora i selektivnog MAO-B inhibitora s entakaponom (vidjeti dio 4.5).
Entacapone should be given cautiously to patients who are taking other medicinal products which may cause orthostatic hypotension. 
Entakapon treba davati s oprezom bolesnicima koji uzimaju druge lijekove koji mogu izazvati ortostatsku hipotenziju.
Pharmacokinetic interaction with benserazide has not been studied. 
Farmakokinetska interakcija s benzerazidom nije ispitivana.
Caution should be exercised when these medicinal products are used concomitantly with entacapone (see also sections 4.3 and 4.4). 
Kada se ovi lijekovi koriste istovremeno s entakaponom potreban je oprez (vidjeti također dijelove 4.3 and 4.4).
To reduce levodopa-related dopaminergic adverse reactions, it is often necessary to adjust levodopa dosage within the first days to first weeks after initiating entacapone treatment, according to the clinical condition of the patient (see sections 4.2 and 4.8). 
Da bi se smanjile dopaminergičke nuspojave povezane s levodopom, često je potrebno prilagoditi doziranje levodope tijekom prvih dana ili prvih tjedana od početka liječenja entakaponom, u skladu s kliničkim stanjem bolesnika (vidjeti dijelove 4.2 i 4.8).
The following adverse reactions, listed below in Table 1, have been accumulated both from clinical studies with entacapone and since the introduction of entacapone into the market. 
Sljedeće nuspojave, niže navedene u Tablici 1, prikupljene su i iz kliničkih ispitivanja entakapona i nakon stavljanja entakapona na tržište.
Rhabdomyolysis secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) has been observed rarely in patients with Parkinson's disease. 
Rabdomioliza kao posljedica teških diskinezija ili neuroleptičkog malignog sindroma (NMS) rijetko je opažena u bolesnika s Parkinsonovom bolešću.
Hence, patients who are taking standard levodopa/benserazide preparations may need a larger reduction of levodopa dose when entacapone is initiated. 
Stoga bolesnici koji uzimaju standardne preparate levodope/benzerazida mogu imati potrebu za većim smanjenjem doze levodope pri uvođenju entakapona.
Management of acute overdose is symptomatic. 
Akutno predoziranje liječi se simptomatski.
Entacapone Teva has no effect on relieving the symptoms of Parkinson´s disease unless taken with levodopa. 
Entakapon Teva nema učinak na ublažavanje simptoma Parkinsonove bolesti ako nije uzet s levodopom.
General characteristics of the active substance 
Opća svojstva djelatne tvari
According to in vitro studies, significant displacement is not anticipated at therapeutic concentrations of the medicinal products. 
Prema in vitro ispitivanjima, ne očekuje se značajnije istiskivanje u terapijskim koncentracijama lijekova.
In two phase III double-blind studies in a total of 376 patients with Parkinson's disease and end-ofdose motor fluctuations, entacapone or placebo was given with each levodopa/dopa decarboxylase inhibitor dose. 
U fazi III dvaju dvostruko slijepih ispitivanja s ukupno 376 bolesnika s Parkinsonovom bolešću i motoričkim fluktuacijama pri kraju doze davani su entakapon ili placebo sa svakom dozom levodope/
When considered necessary, withdrawal of entacapone and other dopaminergic treatment should proceed slowly, and if signs and/or symptoms occur despite a slow withdrawal of entacapone, an increase in levodopa dosage may be necessary. 
Kad se pokaže potrebnim, liječenje entakaponom i drugim dopaminergičkim lijekovima treba ukidati polako, a ako se usprkos polaganom ukidanju entakapona pojave znakovi i/ili simptomi, može biti potrebno povećanje doziranja levodope.
The peak concentration (Cmax) in plasma is usually reached about one hour after ingestion of a 200 mg entacapone tablet. 
Vršna koncentracija (Cmax) u plazmi postiže se obično oko jedan sat nakon uzimanja tablete od
At therapeutic concentrations, entacapone does not displace other extensively bound substances (e.g. warfarin, salicylic acid, phenylbutazone, or diazepam), nor is it displaced to any significant extent by any of these substances at therapeutic or higher concentrations. 
U terapijskim koncentracijama entakapon ne istiskuje druge, snažno vezane lijekove (npr. varfarin, salicilnu kiselinu, fenilbutazon ili diazepam) niti ga bilo koji od ovih lijekova može značajnije istisnuti u terapijskim ili višim koncentracijama.
The elimination of entacapone occurs mainly by non-renal metabolic routes. 
Eliminacija entakapona odvija se uglavnom metaboličkim putevima mimo bubrega.
Therefore, do not take Entacapone Teva and iron supplements at the same time. 
Entakapon Teva i preparate željeza u isto vrijeme.
Entacapone in association with levodopa has been associated with isolated cases of excessive daytime somnolence and sudden sleep onset episodes. 
Entakapon udružen s levodopom bio je povezan s izoliranim slučajevima pretjerane pospanosti tijekom dana i epizodama iznenadnog nastupa sna.
A small amount of entacapone, the (E)-isomer, is converted to its (Z)-isomer. 
Mala količina entakapona, (E)-izomer, pretvara se u njegov (Z)-izomer. (E)-izomer čini 95% AUC
Very rare (may affect up to 1 in 10,000 people): - Agitation; - decreased appetite, weight loss; - hives. 
Vrlo rijetko (mogu se javiti u do 1 na 10 000 osoba): - uznemirenost; - smanjeni apetit, gubitak tjelesne težine;
Consequently, adverse dopaminergic reactions may be more frequent when entacapone is added to levodopa/benserazide treatment (see also section 4.8). 
Posljedično, neželjeni dopaminergički učinci mogli bi biti češći nakon dodatka entakapona liječenju levodopom/benzerazidom (vidjeti također dio 4.8).
Entacapone decreases the metabolic loss of levodopa to 3O-methyldopa (3-OMD) by inhibiting the COMT enzyme. 
Entakapon smanjuje metaboličku pretvorbu levodope u 3-Ometildopu (3-OMD) inhibirajući enzim COMT.
Entacapone enhances the effects of levodopa. 
Entakapon pojačava učinke levodope.
In clinical studies the most common adverse reactions leading to discontinuation of entacapone treatment have been gastrointestinal symptoms (e.g. diarrhoea, 2.5%) and increased dopaminergic adverse reactions of levodopa (e.g. dyskinesias, 1.7%). 
Najčešće nuspojave u kliničkim ispitivanjima, koje su zahtijevale prekid liječenja entakaponom, bile su gastrointestinalni simptomi (npr. proljev, 2,5%) i povećane dopaminergičke nuspojave levodope (npr. diskinezije, 1,7%).
Entacapone Teva in association with levodopa may have major influence on the ability to drive and use machines. 
Teva udružen s levodopom može imati velik utjecaj na sposobnost upravljanja vozilima i strojevima.
Some of the side effects are often caused by the increased effects of levodopa therapy and are most common at the start of treatment. 
Nuspojave su često izazvane pojačanim učinkom terapije levodopom i najčešće su na početku liječenja.
You may also use other medicines to treat Parkinson's disease at the same time. 
Istovremeno smijete uzimati i druge lijekove za terapiju Parkinsonove bolesti.
Thus, control of INR is recommended when entacapone treatment is initiated for patients receiving warfarin. 
Zbog toga se preporučuje kontroliranje INR-a kada se entakapon počinje primjenjivati bolesnicima koji primaju varfarin.
Hence, the precautions valid for levodopa treatment should also be taken into account for entacapone treatment. 
Stoga, mjere opreza koje vrijede za liječenje levodopom treba uzeti u obzir i kod liječenja entakaponom.
Rare (may affect up to 1 in 1,000 people): - Rashes; - abnormal results in liver function test. 
Rijetko (mogu se javiti u do 1 na 1000 osoba): - osipi; - abnormalni rezultati pretraga jetrene funkcije.
Therefore, caution should be exercised when driving or using machines. 
Stoga je potreban oprez pri upravljanju vozilima i strojevima.
For patients experiencing diarrhoea, a follow-up of weight is recommended in order to avoid potential excessive weight decrease. 
U bolesnika s proljevom preporučuje se praćenje tjelesne težine kako bi se izbjegla mogućnost prekomjernog gubitka tjelesne težine.
Entacapone thus prolongs the clinical response to levodopa. 
Na taj način entakapon produžuje klinički odgovor na levodopu.
Urine may be discoloured reddish-brown by entacapone, but this is a harmless phenomenon. 
Entakapon može obojiti mokraću crvenkasto-smeđe, no to je bezopasna pojava.
Entacapone Teva taken together with levodopa may lower your blood pressure, which may make you feel light-headed or dizzy. 
Teva uzet zajedno s levodopom može sniziti Vaš krvni tlak zbog čega možete osjetiti laganu ošamućenost ili omaglicu.
If entacapone treatment is discontinued, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms. 
Ako se liječenje entakaponom prekine, nužno je prilagoditi doziranje ostalih lijekova za Parkinsonovu bolest, posebno levodope, kako bi se postigao zadovoljavajući nadzor nad simptomima
Patients being treated with entacapone in association with levodopa and presenting with somnolence and/or sudden sleep onset episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes have resolved (see also section 4.4). 
Bolesnike koji se liječe entakaponom u kombinaciji s levodopom te osjećaju pospanost i/ili imaju epizode iznenadnog nastupa sna treba uputiti da se suzdržavaju od upravljanja vozilima ili od aktivnosti u kojima bi poremećena budnost mogla biti opasna za njih ili druge osobe zbog rizika od teške ozljede ili smrti (npr. rad sa strojevima) sve dok ponavljanje takvih epizoda ne prestane (vidjeti također dio 4.4).
Regarding reproduction toxicity, decreased foetal weight and a slightly delayed bone development were noticed in rabbits at systemic exposure levels in the therapeutic range. 
Vezano uz reproduktivnu toksičnost, zabilježeno je smanjenje težine ploda i malo usporen razvoj kostiju u kunića tretiranih dozama kojima se postižu sistemske razine izloženosti u terapijskom rasponu.
Entacapone Teva may make it harder for you to digest iron. 
Entakapon Teva može otežati probavu željeza.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL (30 film-coated tablets) 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICA (30 filmom obloženih tableta)
Patients with hepatic impairment See section 4.3. 
Bolesnici s oštećenjem funkcije jetre Vidjeti dio 4.3.
The safety of entacapone in infants is unknown. 
Neškodljivost entakapona za dojenče nije poznata.
One 200 mg tablet is taken with each levodopa/dopa decarboxylase inhibitor dose. 
Jedna tableta od 200 mg uzima se sa svakom dozom levodope/inhibitora dopa dekarboksilaze.
Entacapone in association with levodopa has been associated with somnolence and episodes of sudden sleep onset in patients with Parkinson's disease and caution should therefore be exercised when driving or operating machines (see also section 4.7). 
Entakapon udružen s levodopom je povezan sa somnolencijom i epizodama iznenadnog nastupa sna u bolesnika s Parkinsonovom bolešću pa se preporučuje oprez prilikom upravljanja vozilima i rukovanja strojevima (vidjeti također dio 4.7).
Since the introduction into the market, isolated cases of NMS have been reported, especially following abrupt reduction or discontinuation of entacapone and other concomitant dopaminergic medicinal products. 
Otkada se nalazi na tržištu zabilježeni su izolirani slučajevi NMS-a, posebno nakon naglog smanjenja doze ili prekida primjene entakapona i ostalih istovremeno primijenjenih dopaminergičkih lijekova.
Skin, hair, beard and nail discolorations 
Promjene boje kože, kose, brade i noktiju
• The other ingredients in the tablet core are cellulose microcrystalline, povidone, starch pregelatinised, magnesium stearate and in the film-coating are poly(vinyl alcohol), talc, titanium dioxide (E171), macrogol, iron oxide yellow (E172), lecithin (soya), iron oxide red (E172). 
- Drugi sastojci u jezgri tablete su mikrokristalična celuloza, povidon, prethodno geliran škrob, magnezijev stearat, a u ovojnici tablete poli(vinilni alkohol), talk, titanijev dioksid (E171), makrogol, žuti željezov oksid (E172), sojin lecitin, crveni željezov oksid (E172)
There were corresponding decreases in OFF time. 
U „OFF“ fazi uočena su odgovarajuća smanjenja.
Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms. 
Liječnik će s Vama razgovarati o načinima za kontroliranje ili umanjivanje simptoma.
In repeated dose toxicity studies, anaemia most likely due to iron chelating properties of entacapone was observed. 
U ispitivanjima toksičnosti ponovljenih doza opažena je anemija, najvjerojatnije zbog svojstva entakapona da stvara kelate sa željezom.
Reduction of levodopa dosage decreases the severity and frequency of these reactions. 
Smanjenje doze levodope smanjuje težinu i učestalost tih nuspojava.
The prescribing information for these levodopa preparations is applicable to their concomitant use with entacapone. 
Uputa za propisivanje tih preparata levodope primjenjiva je i za njihovu istovremenu primjenu s entakaponom.
Entacapone increases the bioavailability of levodopa from standard levodopa/benserazide preparations 5-10% more than from standard levodopa/carbidopa preparations. 
Entakapon povećava bioraspoloživost levodope iz standardnih preparata levodope/benzerazida za 5-10% više nego iz standardnih preparata levodope/karbidope.
For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered. 
U bolesnika s progresivnom anoreksijom, astenijom i smanjenjem tjelesne težine unutar relativno kratkog vremenskog perioda potrebno je razmisliti o općem liječničkom pregledu, uključujući pretragu jetrene funkcije.
In clinical studies, adverse dopaminergic reactions, e.g. dyskinesia, were more common in patients who received entacapone and dopamine agonists (such as bromocriptine), selegiline or amantadine compared to those who received placebo with this combination. 
U kliničkim ispitivanjima neželjeni dopaminergički učinci, npr. diskinezija, bili su češći u bolesnika koji su primali entakapon i agoniste dopamina (kao bromokriptin), selegilin ili amantadin u usporedbi s onima koji su primali placebo s tom kombinacijom.
Ischemic heart disease events other than myocardial infarction (e.g. angina pectoris) 
Događaji vezani uz ishemijsku srčanu bolest koji ne uključuju infarkt miokarda (npr. angina pektoris)
The bioavailability of entacapone is about 35% after an oral dose. 
Bioraspoloživost entakapona nakon peroralne doze iznosi oko 35%.
The maximum recommended dose is 200 mg ten times daily, i.e. 2,000 mg of entacapone. 
Maksimalna preporučena doza je 200 mg deset puta dnevno, odnosno 2000 mg entakapona.
Renal insufficiency does not affect the pharmacokinetics of entacapone and there is no need for dose adjustment. 
Bubrežna insuficijencija ne utječe na farmakokinetiku entakapona pa nije potrebno posebno prilagođavanje doze.